• Ambrx, BeiGene to develop next-generation biologics biospectrumasia
    March 08, 2019
    Ambrx to receive an upfront payment of $10 million to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates in this collaboration with BeiGene
PharmaSources Customer Service